3B BlackBio DX Share Price | 3B BlackBio DX Stock Screener
3BBLACKBIO
Healthcare Service Provider
Share Price NSE
₹1241.20
▲
19.50 (1.60%)
Share Price BSE
₹1244.05
▲
18.65 (1.52%)
As of May 29, 2026, the 3B BlackBio DX share price (NSE: 3BBLACKBIO) is ₹1,241.20 on NSE and ₹1,244.05 on BSE, up 1.60% from the previous close, with shares trading between ₹1,223.90 and ₹1,273.50, and a 52-week range of ₹1,198.10–₹1,388.05.
Check 3B BlackBio DX 52-week for the annual price range and momentum.
Use the 3B BlackBio DX stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
3B BlackBio DX Market Cap
₹1,060.99 Cr.
3BBLACKBIO P/E Ratio (TTM)
17.70
3B BlackBio DX P/B Ratio
3.45
EPS (TTM)
₹55.66
Dividend Yield
0.33%
Debt to Equity
-
3BBLACKBIO 52 Week High
₹1388.05
3B BlackBio DX 52 Week Low
₹1198.10
Operating Margin
35.00%
Profit Margin
29.63%
3BBLACKBIO Revenue (TTM)
₹27.00
EBITDA
₹13.00
Net Income
₹8.00
Total Assets
₹296.00
Total Equity
₹271.00
3B BlackBio DX Share Price Chart
Screen 3B BlackBio DX share price with an interactive chart. Analyse 3BBLACKBIO price trends and volatility across different timeframes.
3B BlackBio DX Company Profile - Fundamental Screener
Screen 3B BlackBio DX company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for 3BBLACKBIO shares.
Sector
Healthcare Services
Industry
Healthcare Service Provider
Sub-Sector
Healthcare Service Provider
Segment
E
ISIN
INE994E01018
3B BlackBio DX Balance Sheet Screener
Screen 3BBLACKBIO balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 296 | 248 | 214 | 192 | 194 | 45 | 36 | 30 | 26 | 24 |
| Current Assets | 132 | 123 | 114 | 82 | 118 | 39 | 32 | 26 | 22 | 21 |
| Fixed Assets | 7 | 7 | 8 | 7 | 5 | 4 | 4 | 4 | 3 | 3 |
| Liabilities | ||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 6 | 5 | 4 | 3 | 2 | 2 | 3 | 3 | 4 | 3 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 271 | 226 | 196 | 172 | 148 | 34 | 23 | 19 | 11 | 10 |
| Share Capital | 9 | 9 | 9 | 8 | 8 | 8 | 6 | 6 | 6 | 6 |
| Reserves & Surplus | 260 | 215 | 185 | 146 | 125 | 25 | 16 | 12 | 5 | 4 |
3B BlackBio DX Income Statement Screener - Profit & Revenue Analysis
Screen 3B BlackBio DX income statement and profit fundamentals.
Analyze 3BBLACKBIO quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for 3B BlackBio DX share price evaluation.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec | 2022-Mar | 2022-Jun | 2022-Sept |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 27 | 27 | 39 | 56 | 27 | 23 | 33 | 28 | 19 | 17 | 22 | 20 | 20 | 13 | 19 |
| Expenses | 15 | 10 | 19 | 29 | 13 | 9 | 13 | 10 | 11 | 8 | 11 | 9 | 13 | 7 | 8 |
| EBITDA | 13 | 16 | 20 | 27 | 14 | 15 | 20 | 18 | 9 | 9 | 11 | 12 | 8 | 6 | 11 |
| Operating Profit % | 35.00% | 53.00% | 43.00% | 43.00% | 43.00% | 56.00% | 56.00% | 59.00% | 41.00% | 45.00% | 41.00% | 50.00% | 32.00% | 44.00% | 53.00% |
| Depreciation | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 13 | 16 | 20 | 27 | 14 | 14 | 19 | 18 | 8 | 9 | 10 | 11 | 8 | 6 | 11 |
| Tax | 5 | 3 | 5 | 4 | 5 | 3 | 4 | 4 | 3 | 2 | 3 | 3 | 3 | 2 | 3 |
| Net Profit | 8 | 13 | 15 | 22 | 9 | 11 | 15 | 14 | 5 | 7 | 8 | 9 | 5 | 5 | 8 |
| EPS | 9.38 | 14.76 | 17.55 | 26.19 | 10.26 | 13.19 | 17.35 | 15.75 | 6.94 | 8.41 | 8.86 | 9.94 | 6.43 | 6.28 | 9.70 |
3B BlackBio DX Cash Flow Screener - Liquidity Fundamentals
Screen 3BBLACKBIO cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 43 | 27 | 20 | 37 | 98 | 7 | 4 | 2 | 1 | 1 |
| Investing Activities | -34 | -20 | 15 | -28 | -70 | -1 | -1 | -1 | 0 | 0 |
| Financing Activities | -3 | -4 | -5 | -15 | -2 | 1 | -1 | 0 | 0 | -1 |
| Net Cash Flow | 7 | 3 | 30 | -6 | 26 | 7 | 2 | 1 | 0 | 0 |
3B BlackBio DX Shareholding Pattern Screener
See 3B BlackBio DX shareholding pattern with promoter, FII, and DII holdings.
Check 3B BlackBio DX promoter holding and ownership changes for 3BBLACKBIO on TickJournal.
| Item | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 40.94% | 41.28% | 41.28% | 41.28% | 41.28% | 41.29% | 41.29% | 41.29% |
| FII Holding | 2.57% | 2.57% | 2.64% | 2.70% | 2.49% | 2.68% | 3.27% | 3.28% |
| DII Holding | 1.98% | 1.88% | 1.82% | 1.76% | 1.60% | 1.74% | 1.96% | 1.96% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 37.73% | 38.09% | 43.53% | 43.17% | 43.31% | 42.80% | 42.41% | 42.22% |
| Other Holding | 16.78% | 16.19% | 10.73% | 11.09% | 11.32% | 11.49% | 11.07% | 11.26% |
| Shareholder Count | 10,616 | 10,507 | 10,709 | 10,619 | 10,345 | 10,166 | 9,586 | 9,399 |
3B BlackBio DX Share Dividend Screener - Share Yield Analysis
Check 3B BlackBio DX dividend history with payout and yield data.
View 3B BlackBio DX dividend details including ex-dates and amounts for 3BBLACKBIO stock.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹4.00 | 0.36% |
| 2024-March | ₹3.00 | 0.19% |
| 2023-March | ₹2.50 | 0.32% |
| 2022-March | ₹10.50 | 2.62% |
| 2021-March | ₹9.00 | 2.64% |
| 2020-March | ₹0.70 | 0.25% |
| 2019-March | ₹0.50 | 0.69% |
| 2018-March | ₹0.50 | 0.66% |
| 2017-March | ₹0.30 | 0.22% |
3B BlackBio DX Stock Index Membership
See which indices include 3B BlackBio DX stock.
Check 3BBLACKBIO index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
3B BlackBio DX Market Events Screener - Corporate Actions
Get 3B BlackBio DX corporate actions including splits, bonuses, and buybacks.
Check 3B BlackBio DX stock events that may affect 3BBLACKBIO share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Annual General Meeting | NA | -8.48% | ||
| Dividend | ₹ 1.00 /share | 16.71% | ||
| Dividend | ₹ 8.00 /share | 16.71% | ||
| Annual General Meeting | NA | -4.62% | ||
| Dividend | ₹ 2.50 /share | 3.50% | ||
| Dividend | ₹ 2.50 /share | 87.10% | ||
| Dividend | ₹ 4.00 /share | -29.01% | ||
| Dividend | ₹ 3.00 /share | 79.92% | ||
| 2026-05-29 | 2026-05-29 | Quarterly Result Announcement | NA | -4.58% |
| 2026-02-06 | 2026-02-06 | Quarterly Result Announcement | NA | -2.84% |
| 2025-11-13 | 2025-11-13 | Quarterly Result Announcement | NA | 0.77% |
| 2025-08-14 | 2025-08-14 | Quarterly Result Announcement | NA | 3.22% |
| 2025-05-28 | 2025-05-28 | Quarterly Result Announcement | NA | 15.56% |
| 2025-02-13 | 2025-02-13 | Quarterly Result Announcement | NA | -6.07% |
| 2024-11-13 | 2024-11-13 | Quarterly Result Announcement | NA | -3.07% |
3B BlackBio DX Competitors Screener - Peer Comparison
Screen 3BBLACKBIO competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Dr. Lal Path Labs | 27,058 | 53.50 | 2,763 | 8.15% | 510 | 57.10 |
| Vijaya Diagnostic Centre | 12,558 | 72.87 | 814 | 16.36% | 182 | 55.51 |
| Metropolis Healthcare | 10,874 | 56.27 | 1,646 | 22.25% | 185 | 57.49 |
| Thyrocare Technologies | 7,849 | 45.59 | 829 | 18.06% | 156 | 69.18 |
| Nephrocare Health Services | 6,222 | 79.31 | 999 | 29.74% | 62 | 60.28 |
| Krsnaa Diagnostics | 1,797 | 22.68 | 743 | 16.70% | 78 | 34.34 |
| Suraksha Diagnostic | 1,555 | 51.38 | 310 | 21.30% | 34 | 53.40 |
| 3B BlackBio DX | 1,061 | 17.70 | 112 | 28.72% | 48 | 45.20 |
| Health X Platform | 1,026 | 33.22 | 1,171 | -18.47% | -134 | 69.84 |
| One Global Service Provider | 883 | 14.78 | 148 | 134.60% | 19 | 43.09 |
3B BlackBio DX Company Announcements - News Screener
Screen 3BBLACKBIO latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-05-27 | Compliances-Reg.24(A)-Annual Secretarial Compliance | - |
| 2026-05-25 | Board Meeting Intimation for Consideration And Approval Of Audited Financial Results (Standalone And Consolidated) For Quarter / Financial Year Ended 31St March 2026 And To Discuss Matter Of Recommendation Of Dividend If Any For Financial Year Ended 31S | - |
| 2026-05-14 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-04-21 | Securities Of The Companies Permitted To Trade And Admitted To Dealings On The National Stock Exchange | - |
| 2026-04-15 | Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2 | - |
| 2026-04-15 | Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2 | - |
| 2026-04-14 | Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A | - |
| 2026-04-06 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-04-04 | Disclosure Under Regulation 31(4) Of SEBI (SAST) Regulations 2011 | - |
| 2026-04-04 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-03-26 | Closure of Trading Window | - |
| 2026-03-17 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | - |
| 2026-03-12 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-03-02 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-02-24 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | - |
| 2026-02-21 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | - |
| 2026-02-19 | Letter To Shareholders From CEO | - |
| 2026-02-18 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-02-07 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-02-06 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |